Mindray(SZ:300760) Di Yi Cai Jing·2025-04-06 03:28Core Viewpoint - The company has demonstrated resilience in the face of U.S. tariffs, maintaining a compound annual growth rate (CAGR) of 10% in its U.S. business from 2018 to 2023, with U.S. sales accounting for approximately 6% of total revenue [1][2] Group 1: Impact of Tariffs - The U.S. government announced "reciprocal tariffs" on all trade partners, including China, leading to a 2% drop in the company's stock price [1] - The company has proactively prepared for tariff impacts by stockpiling products based on anticipated orders prior to the implementation of new tariffs [1] - Despite tariffs imposed since the U.S.-China trade war began in 2018, the company has successfully expanded its U.S. market presence [1] Group 2: Financial Performance - The company's gross margin in the U.S. market has exceeded 70%, with profit margins surpassing pre-tariff levels since 2018 [2] - For the first three quarters of 2024, the company reported a revenue of 29.485 billion yuan, reflecting a year-on-year growth of 7.99% [2] - International markets have seen growth exceeding 18%, driven by high-end strategic clients and breakthroughs in various sectors, with Europe and Asia-Pacific markets growing over 30% [2] Group 3: Product Development and Market Strategy - The company is set to receive FDA approval for its ultra-high-end ultrasound product, Resona A20, which has an average selling price (ASP) double that of its predecessor [2] - The company aims to enhance its brand and technology in the U.S. market to strengthen its influence in developing countries, which account for two-thirds of its overseas revenue [2] - The company's main product lines cover three key areas: life information and support, in vitro diagnostics, and medical imaging [2]